Cargando…

Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment

BACKGROUND: Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence of underlying Alzheimer’s disease (AD) pathology in mild cognitive impairment (MCI). However, CSF biomarker-based classification often results in conflicting profiles with controversial prognostic value. Normali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baldeiras, Inês, Santana, Isabel, Leitão, Maria João, Gens, Helena, Pascoal, Rui, Tábuas-Pereira, Miguel, Beato-Coelho, José, Duro, Diana, Almeida, Maria Rosário, Oliveira, Catarina Resende
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861634/ https://www.ncbi.nlm.nih.gov/pubmed/29558986 http://dx.doi.org/10.1186/s13195-018-0362-2

Ejemplares similares

Lower CSF Amyloid-Beta(1–42) Predicts a Higher Mortality Rate in Frontotemporal Dementia
por: Vieira, Daniela, et al.
Publicado: (2019)

Prognosis of Early-Onset vs. Late-Onset Mild Cognitive Impairment: Comparison of Conversion Rates and Its Predictors
por: Tábuas-Pereira, Miguel, et al.
Publicado: (2016)

Neuropsychological features of progranulin-associated frontotemporal dementia: a nested case-control study
por: Lima, Marisa, et al.
Publicado: (2020)

Patients with progranulin mutations overlap with the progressive dysexecutive syndrome: towards the definition of a frontoparietal dementia phenotype
por: Tábuas-Pereira, Miguel, et al.
Publicado: (2020)

Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease
por: Baldeiras, Inês, et al.
Publicado: (2019)

Exome Sequencing of a Portuguese Cohort of Frontotemporal Dementia Patients: Looking Into the ALS-FTD Continuum
por: Tábuas-Pereira, Miguel, et al.
Publicado: (2022)

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease
por: Leitão, Maria João, et al.
Publicado: (2019)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
por: Llorens, Franc, et al.
Publicado: (2017)

Reconsidering the role of blood-brain barrier in Alzheimer’s disease: From delivery to target
por: Sousa, João André, et al.
Publicado: (2023)

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
por: Llorens, Franc, et al.
Publicado: (2020)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease
por: Sweeney, Melanie D, et al.
Publicado: (2015)

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015)

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease
por: Dorey, Aline, et al.
Publicado: (2015)

Simian Varicella Virus Infection and Reactivation in Rhesus Macaques Trigger Cytokine and Aβ40/42 Alterations in Serum and Cerebrospinal Fluid
por: Niemeyer, Christy S, et al.
Publicado: (2023)

Cerebrospinal beta-amyloid peptides(1-40) and (1-42) in severe preeclampsia and HELLP syndrome – a pilot study
por: Lederer, Wolfgang, et al.
Publicado: (2020)

Beta-amyloid peptides(1–42) and (1–40) in the cerebrospinal fluid during pregnancy: a prospective observational study
por: Alomar-Dominguez, Cristina, et al.
Publicado: (2020)

Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers
por: Leitão, Maria João, et al.
Publicado: (2015)

β-Amyloid (1–42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer's Disease
por: Kaiser, Elmar, et al.
Publicado: (2011)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

Low Cerebrospinal Fluid Aβ(42) and Aβ(40) are Related to White Matter Lesions in Cognitively Normal Elderly
por: Skoog, Ingmar, et al.
Publicado: (2018)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
por: Wilczyńska, Karolina, et al.
Publicado: (2020)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Aspects Operationnels 40 41 et 42
por: Boutheon, M
Publicado: (1978)

Sporadic Creutzfeldt-Jakob Disease Causing a 2-Years Slowly Progressive Isolated Dementia
por: Machado, Álvaro, et al.
Publicado: (2009)

Clinical Experience with Cerebrospinal Fluid Aβ(42), Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia
por: Tariciotti, Leonardo, et al.
Publicado: (2018)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients
por: Zerr, Inga, et al.
Publicado: (2019)

Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias
por: Baiardi, Simone, et al.
Publicado: (2018)

The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort
por: Amft, Michaela, et al.
Publicado: (2022)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

A selenium species in cerebrospinal fluid predicts conversion to Alzheimer’s dementia in persons with mild cognitive impairment
por: Vinceti, Marco, et al.
Publicado: (2017)

Experimental mass excess of $^{40}$Cl and $^{42}$Cl
por: Miehé, C, et al.
Publicado: (1989)

Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis
por: Andrés-Benito, Pol, et al.
Publicado: (2020)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
por: Suire, Caitlin N., et al.
Publicado: (2020)

The Cerebrospinal Fluid Aβ(1–42)/Aβ(1–40) Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting
por: Niemantsverdriet, Ellis, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a26im1hpifi2drj0qjl1e6t6ft